Reply to thread

Now it makes sense that a spokesperson for Amgen said that the potential sales of Repatha were being highly exaggerated by managed care companies. They probably do know the results and how limited in scope the "appropriate patient type" will be. Hopefully it won't be as restrictive as Corlanor PI. Might as well go hunting for wild rhinos in Jersey because they are just as rare as appropriate Corlanor patient. Might be time to polish the old resume. Not feeling the confidence on this one.